LACTOLOGY FOUNDATION

A03CA06 comprises combinations of the synthetic anticholinergic agent bevonium with psycholeptic drugs, used as antispasmodics for functional gastrointestinal disorders, typically when a sedative or anxiolytic component is desired.medpedia.framar+2

Pharmacological class and composition

A03CA06 belongs to the ATC group “synthetic anticholinergic agents in combination with psycholeptics” within drugs for functional gastrointestinal disorders.atcddd.fhi+1
Bevonium is described as an antimuscarinic (synthetic anticholinergic) agent that reduces smooth muscle spasms in the gastrointestinal tract.drugcentral+1
Psycholeptics are centrally acting drugs with sedative or anxiolytic effects, added to decrease visceral sensitivity, anxiety, and symptom perception in patients with functional GI complaints.medpedia.framar+1

Mechanism of action and clinical use

Bevonium blocks muscarinic acetylcholine receptors on smooth muscle, leading to reduced motility and spasm, and decreased secretions in the gut.drugcentral+1
Through this anticholinergic effect, bevonium–psycholeptic combinations act as antispasmodics in conditions such as irritable bowel–type functional disorders, painful spasms, and other non-structural gastrointestinal complaints.drugcentral
The psycholeptic component (often a benzodiazepine or other sedative) contributes anxiolysis, sedation, and attenuation of central processing of visceral pain, which may improve overall symptom control in selected patients.sps+1

Toxicological profile

Anticholinergic toxicity is dominated by peripheral and central muscarinic blockade: dry mouth, decreased sweating, tachycardia, urinary retention, constipation, blurred vision, and potential confusion or agitation in susceptible patients.derangedphysiology+2
Because bevonium is a quaternary ammonium antimuscarinic, it is expected to have limited penetration through the blood–brain barrier, which reduces central anticholinergic toxicity but does not eliminate peripheral adverse effects.derangedphysiology+1
Psycholeptics add dose-dependent central nervous system depression, including sedation, psychomotor impairment, and—at high doses or in combination with other CNS depressants—risk of respiratory depression and prolonged somnolence.sps+1
Contraindications include known hypersensitivity to bevonium or any component of the combination, and to the specific psycholeptic(s), as well as caution or avoidance in conditions aggravated by anticholinergics (narrow-angle glaucoma, severe prostatic hypertrophy, certain tachyarrhythmias).medpedia.framar+1
Misuse or overdose of such combinations may produce anticholinergic syndrome together with deep sedation, requiring supportive care, monitoring of cardiac rhythm, and in some cases use of specific antagonists (e.g. physostigmine for severe anticholinergic toxicity, flumazenil for selected benzodiazepine overdose).sps+1

Use in pregnancy and lactation

There are no robust, modern lactation-specific pharmacokinetic data for bevonium combinations, and A03CA06 products are uncommon or unavailable in many markets; therefore, evidence-based lactation risk assessments must rely on class principles.druginfo+1
Anticholinergics used systemically may be excreted into breast milk in low amounts, and clinical guidance suggests that most medicines excreted at less than 10% of the maternal dose in milk are generally compatible with breastfeeding, provided infant monitoring is in place.medsafe
Quaternary ammonium antimuscarinics tend to have poor oral bioavailability and limited systemic penetration, which theoretically reduces exposure and clinical effect in the breastfed infant, but this cannot be assumed without product-specific data.medsafe+1
The psycholeptic component poses the main lactational concern: benzodiazepines and other sedatives can cause infant sedation, feeding difficulties, and hypotonia, particularly in premature or medically fragile infants, so guidelines recommend using the lowest effective dose, short half-life agents, and close monitoring if they are used at all.medsafe+1
General lactation advice emphasises using medicines with short half-life, low oral bioavailability, high protein binding, and high molecular weight when possible, and timing breastfeeding immediately before maternal dosing to minimise peak exposure.mayoclinic+1
In the absence of specific data for bevonium–psycholeptic products, such combinations should be avoided during breastfeeding when alternatives exist; if use is unavoidable, this warrants individualised risk–benefit assessment, minimised dosing, and monitoring of the infant for sedation, poor feeding, and gastrointestinal effects.mayoclinic+2

Practical prescribing considerations

Indications for A03CA06 medicines are antispasmodic treatment of functional gastrointestinal disorders, not structural pathology; they are typically prescription-only medicines.medpedia.framar+1
Before initiation, clinicians should evaluate comorbidities (cardiac disease, glaucoma, urinary outflow obstruction, cognitive impairment) and concurrent CNS depressants, as these factors increase toxicity risk.sps+1
During use in breastfeeding women, the preference is usually for non-sedating alternatives and single-agent therapy, and any psycholeptic co-medication should follow specialised breastfeeding guidance and, where available, lactation-specific resources.mayoclinic+2